Cargando…
Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Thoracic Society
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020728/ https://www.ncbi.nlm.nih.gov/pubmed/32969708 http://dx.doi.org/10.1164/rccm.202008-3176LE |
| _version_ | 1783674621872046080 |
|---|---|
| author | Griese, Matthias Costa, Stefano Linnemann, Rachel W. Mall, Marcus A. McKone, Edward F. Polineni, Deepika Quon, Bradley S. Ringshausen, Felix C. Taylor-Cousar, Jennifer L. Withers, Nicholas J. Moskowitz, Samuel M. Daines, Cori L. |
| author_facet | Griese, Matthias Costa, Stefano Linnemann, Rachel W. Mall, Marcus A. McKone, Edward F. Polineni, Deepika Quon, Bradley S. Ringshausen, Felix C. Taylor-Cousar, Jennifer L. Withers, Nicholas J. Moskowitz, Samuel M. Daines, Cori L. |
| author_sort | Griese, Matthias |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8020728 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | American Thoracic Society |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-80207282021-04-05 Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial Griese, Matthias Costa, Stefano Linnemann, Rachel W. Mall, Marcus A. McKone, Edward F. Polineni, Deepika Quon, Bradley S. Ringshausen, Felix C. Taylor-Cousar, Jennifer L. Withers, Nicholas J. Moskowitz, Samuel M. Daines, Cori L. Am J Respir Crit Care Med Correspondence American Thoracic Society 2021-02-01 2021-02-01 /pmc/articles/PMC8020728/ /pubmed/32969708 http://dx.doi.org/10.1164/rccm.202008-3176LE Text en Copyright © 2021 by the American Thoracic Society https://creativecommons.org/licenses/by-nc-nd/4.0/This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/). For commercial usage and reprints, please contact Diane Gern (dgern@thoracic.org). |
| spellingShingle | Correspondence Griese, Matthias Costa, Stefano Linnemann, Rachel W. Mall, Marcus A. McKone, Edward F. Polineni, Deepika Quon, Bradley S. Ringshausen, Felix C. Taylor-Cousar, Jennifer L. Withers, Nicholas J. Moskowitz, Samuel M. Daines, Cori L. Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial |
| title | Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial |
| title_full | Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial |
| title_fullStr | Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial |
| title_full_unstemmed | Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial |
| title_short | Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial |
| title_sort | safety and efficacy of elexacaftor/tezacaftor/ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more f508del alleles: interim results of an open-label phase 3 clinical trial |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020728/ https://www.ncbi.nlm.nih.gov/pubmed/32969708 http://dx.doi.org/10.1164/rccm.202008-3176LE |
| work_keys_str_mv | AT griesematthias safetyandefficacyofelexacaftortezacaftorivacaftorfor24weeksorlongerinpeoplewithcysticfibrosisandoneormoref508delallelesinterimresultsofanopenlabelphase3clinicaltrial AT costastefano safetyandefficacyofelexacaftortezacaftorivacaftorfor24weeksorlongerinpeoplewithcysticfibrosisandoneormoref508delallelesinterimresultsofanopenlabelphase3clinicaltrial AT linnemannrachelw safetyandefficacyofelexacaftortezacaftorivacaftorfor24weeksorlongerinpeoplewithcysticfibrosisandoneormoref508delallelesinterimresultsofanopenlabelphase3clinicaltrial AT mallmarcusa safetyandefficacyofelexacaftortezacaftorivacaftorfor24weeksorlongerinpeoplewithcysticfibrosisandoneormoref508delallelesinterimresultsofanopenlabelphase3clinicaltrial AT mckoneedwardf safetyandefficacyofelexacaftortezacaftorivacaftorfor24weeksorlongerinpeoplewithcysticfibrosisandoneormoref508delallelesinterimresultsofanopenlabelphase3clinicaltrial AT polinenideepika safetyandefficacyofelexacaftortezacaftorivacaftorfor24weeksorlongerinpeoplewithcysticfibrosisandoneormoref508delallelesinterimresultsofanopenlabelphase3clinicaltrial AT quonbradleys safetyandefficacyofelexacaftortezacaftorivacaftorfor24weeksorlongerinpeoplewithcysticfibrosisandoneormoref508delallelesinterimresultsofanopenlabelphase3clinicaltrial AT ringshausenfelixc safetyandefficacyofelexacaftortezacaftorivacaftorfor24weeksorlongerinpeoplewithcysticfibrosisandoneormoref508delallelesinterimresultsofanopenlabelphase3clinicaltrial AT taylorcousarjenniferl safetyandefficacyofelexacaftortezacaftorivacaftorfor24weeksorlongerinpeoplewithcysticfibrosisandoneormoref508delallelesinterimresultsofanopenlabelphase3clinicaltrial AT withersnicholasj safetyandefficacyofelexacaftortezacaftorivacaftorfor24weeksorlongerinpeoplewithcysticfibrosisandoneormoref508delallelesinterimresultsofanopenlabelphase3clinicaltrial AT moskowitzsamuelm safetyandefficacyofelexacaftortezacaftorivacaftorfor24weeksorlongerinpeoplewithcysticfibrosisandoneormoref508delallelesinterimresultsofanopenlabelphase3clinicaltrial AT dainescoril safetyandefficacyofelexacaftortezacaftorivacaftorfor24weeksorlongerinpeoplewithcysticfibrosisandoneormoref508delallelesinterimresultsofanopenlabelphase3clinicaltrial |